Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  News  >  Economy & Forex

News : Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
All NewsEconomyCurrencies & ForexEconomic EventsCryptocurrenciesCybersecurityPress Releases

PhRMA - Pharmaceutical Research and Manufacturers : PDUFA V Sets New Course for Regulatory Science – Joint BIO/PhRMA Statement

share with twitter share with LinkedIn share with facebook
10/01/2012 | 10:23am EDT

Washington, D.C. (October 1, 2012) - Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John J. Castellani and Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood today released the following joint statement on the implementation of the Prescription Drug User Fee Act (PDUFA V):

"Today, as implementation of PDUFA V officially commences, PhRMA and BIO stand together to usher in an exciting new era in regulatory science - a period that holds great promise for bringing new, innovative medicines to patients in a timely manner.

"A reliable, science-driven regulatory environment fosters innovation, promotes economic competitiveness and helps maintain high patient confidence in the integrity of our medicines. PDUFA V, reauthorized in July 2012 as part of the Food and Drug Administration Safety and Innovation Act (FDASIA), is a significant step in this direction.

"If implemented successfully, PDUFA V will refocus the program on its original intent - timely patient access to new medicines - while strengthening FDA's high safety standards and helping to establish a new system-wide approach to regulatory science that embraces the scientific tools used in 21st century drug development.

"Among its many forward-looking provisions, PDUFA V will enable more timely patient access to safe and effective new medicines through enhanced scientific communications with sponsors during drug development and throughout the drug review process. It also will support the development of a framework to facilitate benefit/risk evaluations of new medicines and integrate patient perspectives in the review process, with a particular focus on diseases with considerable unmet needs.

"Under PDUFA V, FDA will have increased resources and staffing to validate the use of new scientific tools, such as pharmacogenomics and biomarkers, that can help demonstrate therapeutic benefits more rapidly. The Agency also will have dedicated resources to evaluate the use of meta-analyses and provide guidance on standardized methodologies for their use in drug review and safety monitoring.

"In addition, FDA will have the resources to further strengthen its already robust focus on patient safety by standardizing risk evaluation and mitigation strategies (REMS) and helping to make them less burdensome to implement for the healthcare community.

share with twitter share with LinkedIn share with facebook
Latest news "Economy & Forex"
05:34aGerman Retail Sales Expected to Increase in 2020 Despite Coronavirus
DJ
05:16aNEWS HIGHLIGHTS : Top Global Markets News of the Day
DJ
05:16aNEWS HIGHLIGHTS : Top Company News of the Day
DJ
05:05aGreek Merchant Fleet (Provisional Data), July 2020
PU
05:05aEL STAT HELLENIC STATISTICAL AUTHORITY : Evolution of Turnover of Enterprises in Accommodation and Food Service Activities Section, July 2020
PU
05:00aDollar bounces back as Europe sets for a second wave
PU
05:00aOECD ORGANISATION FOR ECONOMIC OPERATION AND : to launch new PISA report on school policies and practices on Tuesday 29 September 2020
PU
04:56aGerman Economy Seen Shrinking Less in 2020 Than Previously Expected -- Ifo Institute
DJ
04:30aRiksbank Still Sees Repo Rate Stuck at Zero in Coming Years
DJ
04:28aDeutsche bank executive says coronavirus has changed customer behavior
RE
Latest news "Economy & Forex"